| Variables |
Diabetes (n = 302) |
Non-diabetes (n = 127) |
| Poor (n = 125) |
Good (n = 177) |
Pvalue |
Poor (n = 33) |
Good (n = 94) |
Pvalue |
| Female, n (%) |
41 (33.1) |
33 (18.8) |
0.005 |
11 (33.3) |
14 (14.9) |
0.02 |
| Age, y |
65.5 ± 9.8 |
64.0 ± 11.0 |
0.23 |
67.9 ± 10.0 |
63.6 ± 10.2 |
0.04 |
| Body mass index, Kg/m2 |
25.1 ± 3.5 |
24.8 ± 3.3 |
0.43 |
26.5 ± 3.0 |
24.9 ± 3.2 |
0.01 |
| Smoke, n (%) |
50 (40.0) |
60 (33.9) |
0.28 |
13 (39.4) |
43 (45.7) |
0.53 |
| Hypertension, n (%) |
77 (61.6) |
133 (75.1) |
0.01 |
18 (54.5) |
69 (73.4) |
0.045 |
| Dyslipidemia, n (%) |
70 (56.0) |
75 (42.4) |
0.02 |
20 (60.6) |
34 (36.2) |
0.02 |
| Systolic blood pressure, mm Hg |
137.5 ± 18.3 |
140.9 ± 16.5 |
0.09 |
139.5 ± 20.0 |
140.8 ± 21.1 |
0.75 |
| Diastolic blood pressure, mm Hg |
82.8 ± 10.5 |
85.0 ± 8.7 |
0.05 |
83.4 ± 13.3 |
83.9 ± 9.7 |
0.82 |
| Fasting blood glucose, mmol/L |
6.0 ± 2.0 |
5.7 ± 1.6 |
0.15 |
5.3 ± 0.7 |
5.0 ± 0.6 |
0.03 |
| HbA1c, % |
6.7 ± 1.3 |
6.5 ± 1.6 |
0.30 |
5.9 ± 0.3 |
5.8 ± 0.4 |
0.09 |
| Severity of coronary artery disease, n (%) |
|
|
0.10 |
|
|
0.68 |
| 1-vessel |
29 (23.2) |
26 (14.7) |
|
5 (15.2) |
11 (11.7) |
|
| 2-vessel |
35 (28.0) |
65 (36.7) |
|
14 (42.4) |
35 (37.2) |
|
| 3-vessel |
61 (48.8) |
86 (48.6) |
|
14 (42.4) |
48 (51.1) |
|
| Triglyceride, mmol/L |
1.9 ± 0.9 |
1.8 ± 1.3 |
0.37 |
1.8 ± 0.9 |
1.7 ± 0.9 |
0.63 |
| Total cholesterol, mmol/L |
4.5 ± 1.5 |
4.3 ± 1.2 |
0.29 |
3.9 ± 1.1 |
4.3 ± 1.2 |
0.16 |
| HDL-cholesterol, mmol/L |
0.99 ± 0.25 |
1.05 ± 0.29 |
0.04 |
0.93 ± 0.21 |
1.02 ± 0.25 |
0.07 |
| LDL-choleterol, mmol/L |
2.7 ± 1.2 |
2.5 ± 1.0 |
0.07 |
2.5 ± 1.0 |
2.7 ± 1.1 |
0.32 |
| Blood urea nitrogen, mmol/L |
5.5 ± 1.7 |
5.4 ± 1.5 |
0.46 |
5.1 ± 1.8 |
5.1 ± 1.9 |
0.92 |
| Uric acid, μmol/L |
338 ± 82 |
325 ± 83 |
0.17 |
345 ± 62 |
345 ± 90 |
1.00 |
| Creatinine,μmol/L |
81 (71 ~ 93) |
72 (64 ~ 85) |
<0.001 |
85 (76 ~91) |
79 (65 ~ 92) |
0.12 |
| Cystatin C, mg/L |
1.07 (0.85 ~ 1.14) |
0.80 (0.69 ~ 0.90) |
< 0.001 |
1.12 (0.81 ~ 1.24) |
0.86 (0.68 ~ 1.12) |
0.002 |
| GFRMDRD, mL/min/1.73m2 |
86.3 (71.9 ~ 99.5) |
100.0 (85.0 ~ 119.1) |
< 0.001 |
83.2 (71.6 ~ 90.7) |
95.9 (77.3 ~ 114.9) |
0.006 |
| GFREPI, mL/min/1.73m2 |
85.8 (71.1 ~ 96.0) |
95.0 (83.3 ~ 102.6) |
< 0.001 |
78.7 (68.6 ~ 90.3) |
93.0 (76.1 ~ 101.9) |
0.004 |
| GFRCYS, mL/min/1.73m2 |
68.9 (61.5 ~ 94.4) |
101.6 (84.5 ~ 111.2) |
< 0.001 |
58.9 (55.8 ~ 96.6) |
97.1 (65.8 ~ 111.1) |
< 0.001 |
| Medication, n (%) |
|
|
|
|
|
|
| ACE inhibitor/ARB |
69 (55.2) |
104 (58.8) |
0.54 |
12 (36.4) |
40 (42.6) |
0.53 |
| β-blocker |
54 (42.7) |
71 (39.8) |
0.59 |
17 (51.5) |
36 (38.3) |
0.19 |
| Calcium channel blocker |
35 (28.2) |
47 (26.7) |
0.78 |
9 (27.3) |
17 (18.1) |
0.26 |
| Nitrates |
74 (59.2) |
113 (64.2) |
0.41 |
13 (39.4) |
42 (44.7) |
0.60 |
| Statins* |
69 (55.2) |
104 (58.8) |
0.54 |
12 (36.4) |
52 (55.3) |
0.06 |
| Antidiabetic therapy |
98 (78.4) |
149 (84.2) |
0.20 |
/ |
/ |
/ |
Data are mean ± SD or median (25th ~ 75th percentiles) or number (%)
ACE, angiotension converting enzyme; ARB, angiotension receptor blocker; GFR, glomerular filtration rate, HbA1c, glycoseylated hemoglobin A1c; HDL, high-density
lipoprotein; LDL, low-density lipoprotein
*Statins: mainly simvastatin, pravastatin and atorvastatin. |
